Tarlatamab + durva significantly improve OS, PFS, and ORR in 1LM ES-SCLC in maintenance setting. Maintenance vs 2L tarlatamab will be discussed and we wait for data in frontline. Anyway DLL3 drugs are definitely changing thepronostic of SCLC. @OncoAlert @myESMO #ESMO26
97 浏览 · 6 赞 · 4 转发 · 0 回复
Sustained survival with extended follow-up of tarlatamab plus anti-PD-L1 as first-line maintenance (1LM) after chemoimmunotherapy for extensive-stage small cell lung cancer (ES-SCLC): DeLLphi-303 phase 1b study
https://esmocongress.esmo.orgCytokine release syndrome in patients receiving tarlatamab for extensive-stage small cell lung cancer: A real-world analysis
https://esmocongress.esmo.orgTarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Julien Mazieres · x.com